CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...